<DOC>
	<DOC>NCT02496078</DOC>
	<brief_summary>The purpose of this study is to determine whether a regimen consisting of daclatasvir and asunaprevir is effective in treatment-naive patients with chronic hepatitis genotype 1b infection.</brief_summary>
	<brief_title>A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Patients chronically infected with HCV Genotype 1b No previous exposure to any interferon formulation, Ribavirin (RBV), and HCV direct acting antiviral agent HCV RNA viral load ≥ 10,000 IU/mL at screening Seronegative for HIV and HBsAg BMI of 1835 kg/m2, inclusive Patients with compensated cirrhosis are permitted Infection with HCV other than genotype (GT) 1b Evidence of decompensated liver disease including, but not limited to, a history or presence of ascites, bleeding varices, or hepatic encephalopathy Evidence of a medical condition contributing to chronic liver disease other than HCV Diagnosed or suspected hepatocellular carcinoma or other malignancies Uncontrolled diabetes or hypertension History of moderate to severe depression. Wellcontrolled mild depression is allowed Confirmed alanine aminotransferase (ALT) ≥ 5x Upper Limit of Normal (ULN) Confirmed platelet count &lt; 50,000 cells/mm3 Confirmed hemoglobin &lt; 8.5 g/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>